Expert Opinion on Investigational Drugs, Volume 29, Issue 2 (2020)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 29, Issue 2 (2020)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Volume 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

NASH and NAFLD: Emerging drugs, therapeutic targets and translational and clinical challenges

Foreword

Introduction
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
Naim Alkhouri
Page: 87
Published online: 29 Jan 2020
CitationforNASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges | Full Text | PDF (177.2 KB) | EPUB
  • 5366 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access

Editorial

Editorial
Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
Sander Lefere, Lindsey Devisscher & Frank Tacke
Pages: 89-92
Published online: 20 Jan 2020
First Page PreviewforTargeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges | Full Text | References | PDF (517.6 KB) | EPUB
  • 6019 Views
  • 25 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) – how are clinical trials affected?
Maurice Michel & Jörn M. Schattenberg
Pages: 93-97
Published online: 21 Jan 2020
First Page PreviewforEffectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) – how are clinical trials affected? | Full Text | References | PDF (548.9 KB) | EPUB
  • 2969 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)
Naim Alkhouri
Pages: 99-101
Published online: 25 Dec 2019
First Page PreviewforThyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) | Full Text | References | PDF (436.3 KB) | EPUB
  • 6880 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access
Editorial
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Herbert Tilg, Maria Effenberger & Timon E. Adolph
Pages: 103-106
Published online: 24 Oct 2019
First Page PreviewforA role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? | Full Text | References | PDF (380.1 KB) | EPUB
  • 3359 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery
Luke V. Selby, Aslam Ejaz, Stacy A. Brethauer & Timothy M. Pawlik
Pages: 107-110
Published online: 27 Jan 2020
First Page PreviewforFatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery | Full Text | References | PDF (497.2 KB) | EPUB
  • 2519 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access

Interview

Discussion
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH)
Jörn M. Schattenberg
Pages: 111-113
Published online: 03 Feb 2020
First Page PreviewforProf Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH) | Full Text | PDF (439.5 KB) | EPUB
  • 1342 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Discussion
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development
Naim Alkhouri
Pages: 115-116
Published online: 03 Feb 2020
CitationforNonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development | Full Text | PDF (265.9 KB) | EPUB
  • 1493 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
Menso J. Westerouen Van Meeteren, Joost P.H. Drenth & Eric T.T.L. Tjwa
Pages: 117-123
Published online: 25 Sep 2019
AbstractforElafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH) | Full Text | References | PDF (604.2 KB) | EPUB
  • 1202 Views
  • 52 CrossRef citations
  • 0Altmetric
Article
Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
Cristy R.C. Verzijl, Ivo P. Van De Peppel, Dicky Struik & Johan W. Jonker
Pages: 125-133
Published online: 03 Jan 2020
AbstractforPegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis | Full Text | References | PDF (984.5 KB) | EPUB
  • 9592 Views
  • 36 CrossRef citations
  • 0Altmetric
Open Access
Article
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
Naim Alkhouri, Eric Lawitz, Mazen Noureddin, Ralph DeFronzo & Gerald I. Shulman
Pages: 135-141
Published online: 19 Sep 2019
AbstractforGS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) | Full Text | References | PDF (849.9 KB) | EPUB
  • 1307 Views
  • 83 CrossRef citations
  • 0Altmetric

Review

Review
Multi-drug approaches to NASH: what’s in the development pipeline?
Michael P Johnston, Janisha Patel & Christopher D Byrne
Pages: 143-150
Published online: 23 Sep 2019
AbstractforMulti-drug approaches to NASH: what’s in the development pipeline? | Full Text | References | PDF (815 KB) | EPUB
  • 986 Views
  • 14 CrossRef citations
  • 0Altmetric
Review
The molecular basis for current targets of NASH therapies
Kamran Qureshi & Brent A. Neuschwander-Tetri
Pages: 151-161
Published online: 18 Dec 2019
AbstractforThe molecular basis for current targets of NASH therapies | Full Text | References | PDF (1,006.5 KB) | EPUB
  • 842 Views
  • 10 CrossRef citations
  • 0Altmetric
Review
Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)
Daren R. Ure, Daniel J. Trepanier, Patrick R. Mayo & Robert T. Foster
Pages: 163-178
Published online: 23 Dec 2019
AbstractforCyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH) | Full Text | References | PDF (1.8 MB) | EPUB
  • 6206 Views
  • 13 CrossRef citations
  • 0Altmetric
Open Access
Review
Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair
Edward J. Jarman & Luke Boulter
Pages: 179-190
Published online: 23 Jan 2020
AbstractforTargeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair | Full Text | References | PDF (1.4 MB) | EPUB
  • 518 Views
  • 8 CrossRef citations
  • 0Altmetric
Review
NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
Jerry Colca
Pages: 191-196
Published online: 23 Jan 2020
AbstractforNASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root | Full Text | References | PDF (681.5 KB) | EPUB
  • 476 Views
  • 9 CrossRef citations
  • 0Altmetric
Review
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Michael Ritchie, Ibrahim A. Hanouneh, Mazen Noureddin, Timothy Rolph & Naim Alkhouri
Pages: 197-204
Published online: 22 Jan 2020
AbstractforFibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? | Full Text | References | PDF (680 KB) | EPUB
  • 1040 Views
  • 23 CrossRef citations
  • 0Altmetric

Original Research

Article
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease
Phuc Le, Alexander Chaitoff, Michael B. Rothberg, Arthur McCullough & Naim Alkhouri
Pages: 205-208
Published online: 24 Dec 2019
AbstractforTrends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease | Full Text | References | PDF (408.7 KB) | EPUB
  • 250 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
Use of a bioengineered antioxidant in mouse models of metabolic syndrome
Deric M. Griffin, Brittany R. Bitner, Zachary Criss Ii, Daniela Marcano, Jacob M. Berlin, Thomas A. Kent, James M. Tour, Susan L. Samson & Robia G. Pautler
Pages: 209-219
Published online: 20 Jan 2020
AbstractforUse of a bioengineered antioxidant in mouse models of metabolic syndrome | Full Text | References | PDF (1.8 MB) | EPUB
  • 204 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles